Form 4: Quantum-Si CFO Boosts Equity Holdings with New Grants

Quantum-Si's Chief Financial Officer, Jeffry R. Keyes, was granted 652,803 restricted stock units and options for 780,847 shares, aligning his interests with long-term shareholder value.

Summary

• Jeffry R. Keyes, Chief Financial Officer of Quantum-Si Inc. (QSI), reported the acquisition of equity securities.
• The grant includes 652,803 restricted stock units (RSUs) at a price of $0 per unit.
• Each RSU represents the right to receive one share of Class A Common Stock upon vesting.
• The RSUs will vest in four equal annual installments, commencing on April 20, 2027, contingent on continued service.
• Following this transaction, Mr. Keyes beneficially owns 1,816,000 shares of Class A Common Stock.
• Additionally, Mr. Keyes was granted stock options to acquire 780,847 shares of Class A Common Stock.
• The exercise price for these stock options is $0.976 per share.
• These stock options will vest in equal quarterly installments, beginning on June 20, 2026, subject to continued service.
• The stock options have an expiration date of March 12, 2036.
• Following this transaction, Mr. Keyes beneficially owns 780,847 derivative securities (stock options).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as it signifies a strong alignment of the Chief Financial Officer's interests with the long-term performance of Quantum-Si, incentivizing sustained commitment and value creation.

Positives

• The significant equity grants to the Chief Financial Officer demonstrate a strong alignment of management's interests with long-term shareholder value.
• Equity awards, particularly with multi-year vesting schedules, serve as a powerful incentive for executive retention and sustained performance.
• Increased insider ownership can signal confidence in the company's future prospects to the market.

Negatives

• The future vesting and exercise of these equity awards could lead to some dilution for existing shareholders, although this is a standard aspect of executive compensation.

Future Outlook

The vesting schedules for both the restricted stock units and stock options indicate a long-term commitment from the Chief Financial Officer, with equity awards vesting over several years, contingent on continued service.

Industry Context

StockSavvy.ai notes that significant equity grants to key executives like the CFO are a common practice in the biotechnology and life sciences sector, particularly for growth-oriented companies like Quantum-Si, to incentivize long-term performance and retention. This aligns executive interests with shareholder value creation over multi-year horizons.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the biotech industry often include a mix of RSUs and stock options, similar to this grant.
• Companies such as Illumina (ILMN) and Pacific Biosciences (PACB) frequently utilize similar structures to attract and retain top talent, with vesting schedules typically ranging from three to five years.
• The size of the grant for Quantum-Si's CFO appears substantial, reflecting the company's stage and the executive's role in its strategic development.

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to aligned executive incentives; potential for future dilution upon vesting/exercise of awards.
• Employees: May view this as a sign of stability and commitment from senior leadership.
• Management: Enhanced personal stake in the company's success, providing strong motivation for performance.

Next Steps

• Continued service of the CFO through applicable vesting dates for RSUs and stock options.
• Vesting of stock options in equal quarterly installments beginning June 20, 2026.
• Vesting of restricted stock units in four equal annual installments beginning April 20, 2027.

Key Dates

Keywords

Quantum-Si, QSI, Form 4, insider transaction, equity compensation, restricted stock units, stock options, CFO, executive compensation